LB Alexandrov, S Nik-Zainal, DC Wedge, SAJR Aparicio, S Behjati, AV Biankin, GR Bignell, N Bolli, A Borg, A-L Børresen-Dale, S Boyault, B Burkhardt, AP Butler, C Caldas, HR Davies, C Desmedt, R Eils, JE Eyfjörd, JA Foekens, M Greaves, F Hosoda, B Hutter, T Ilicic, S Imbeaud, M Imielinski, N Jäger, DTW Jones, D Jones, S Knappskog, M Kool, SR Lakhani, C López-Otín, S Martin, NC Munshi, H Nakamura, PA Northcott, M Pajic, E Papaemmanuil, A Paradiso, JV Pearson, XS Puente, K Raine, M Ramakrishna, AL Richardson, J Richter, P Rosenstiel, M Schlesner, TN Schumacher, PN Span, JW Teague, Y Totoki, ANJ Tutt, R Valdés-Mas, MM van Buuren, L van 't Veer, A Vincent-Salomon, N Waddell, LR Yates, Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, ICGC PedBrain, J Zucman-Rossi, PA Futreal, U McDermott, P Lichter, M Meyerson, SM Grimmond, R Siebert, E Campo, T Shibata, SM Pfister, PJ Campbell, MR Stratton
All cancers are caused by somatic mutations; however, understanding of the biological processes generating these mutations is limited. The catalogue of somatic mutations from a cancer genome bears the signatures of the mutational processes that have been operative. Here we analysed 4,938,362 mutations from 7,042 cancers and extracted more than 20 distinct mutational signatures. Some are present in many cancer types, notably a signature attributed to the APOBEC family of cytidine deaminases, whereas others are confined to a single cancer class. Certain signatures are associated with age of the patient at cancer diagnosis, known mutagenic exposures or defects in DNA maintenance, but many are of cryptic origin. In addition to these genome-wide mutational signatures, hypermutation localized to small genomic regions, 'kataegis', is found in many cancer types. The results reveal the diversity of mutational processes underlying the development of cancer, with potential implications for understanding of cancer aetiology, prevention and therapy.